Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids
The Journal of Allergy and Clinical Immunology: In Practice · 2025
DOI: 10.1016/j.jaip.2024.09.028 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Tsung-Chieh Yao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Medicine, Chang Gun…. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Leukotriene Antagonists, Mental Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Institute of Child Health and Human Development, Chang Gung Medical Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: Leukotriene-receptor antagonists (LTRA) and inhaled corticosteroids (ICS) are common controller medications for asthma, but limited studies examine their comparative risks on neuropsychiatric adverse events (NAEs) in patients with asthma. OBJECTIVE: To investigate the comparative risks of LTRA versus ICS on 7 distinct categories of NAEs in patients with asthma at a nationwide level. METHODS: We conducted a nationwide cohort study during 2010-2021. Incident NAEs and their clinical subgroups (eg, psychotic disorders, anxiety disorders, movement disorders, behavioral and emotional disorders, mood disorders, sleep-related disorders, and personality disorders) were assessed. Cox proportional hazards regressions were used to quantify the comparative risks. RESULTS: There were 1,249,897 patients with asthma aged 6 to 64 years. Incidence rates for NAEs were 25.10 per 1000 person-years among patients treated with LTRA and 23.46 per 1000 person-years among those treated with ICS. The incidence rate difference was 1.64 (95% confidence interval [CI]: 0.30-2.98) per 1000 person-years. Positive associations of NAEs and 3 clinical subgroups were found in patients treated with LTRA compared with ICS (hazard ratios [HR]: 1.06 [95% CI: 1.00-1.12] for NAEs; HR: 1.88 [95% CI: 1.24-2.84] for psychotic disorders; HR: 1.10 [95% CI: 1.01-1.20] for anxiety disorders; and HR: 1.27 [95% CI: 1.02-1.58] for behavioral and emotional disorders), but not for movement disorders, mood disorders, sleep-related disorders, and personality disorders. CONCLUSIONS: This nationwide cohort study identified heightened risks, ranging from 6% to 88%, of NAEs and 3 clinical subgroups in patients with asthma treated with LTRA compared with ICS. These findings underscore the necessity for clinicians to communicate with patients regarding potential neuropsychiatric harms when prescribing LTRA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan. Electronic address:…
- School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan; Department of Pediatrics, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
- National Center for Geriatrics and Welfare Research, National Health Research Institutes, Zhunan, Taiwan; Department of Psychiatry, National Taiwan University Hospital, Yunlin branch, Douliu, Taiwan.
- Institute of Statistics, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
- Department of Pediatrics, Chi-Mei Medical Center, Tainan, Taiwan.
Förderung
- Ministry of Science and Technology, Taiwan
- National Institute of Child Health and Human Development
- Chang Gung Medical Foundation
- National Health Research Institutes
- National Institutes of Health
- National Science and Technology Council
Zitieren
APA
Yao, T. C., Huang, J. L., Wu, C. S., Horng-Shing Lu, H., Chang, Y. C., Chen, W. Y., Kao, H. F., Wu, A. C., & Tsai, H. J. (2025). Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.09.028
Vancouver
Yao TC, Huang JL, Wu CS, Horng-Shing Lu H, Chang YC, Chen WY, et al. Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2024.09.028
BibTeX
@article{Yao2025,
author = {Yao, Tsung-Chieh and Huang, Jing-Long and Wu, Chi-Shin and Horng-Shing Lu, Henry and Chang, Yen-Chen and Chen, Wei-Yu and Kao, Hui-Fang and Wu, Ann Chen and Tsai, Hui-Ju},
title = {Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
doi = {10.1016/j.jaip.2024.09.028}
}
EUVIMED